Capiton-backed KD Pharma Group to acquire Marine Lipids business from dsm-firmenich.

Capiton-backed KD Pharma Group, a CDMO that develops products in the pharmaceutical and nutraceutical sectors, agreed to acquire Marine Lipids business from dsm-firmenich, a company that innovates, manufactures, and combines essential nutrients, flavors, and fragrances to enhance nutrition, health, and beauty. Financial terms were not disclosed. “We are thrilled to welcome dsm-firmenich’s Marine Lipids portfolio into the KD Pharma Group, a move that aligns perfectly with our strategic vision of being technology leaders in lipids and enhancing our ability to innovate and deliver exceptional value to our customers," Oscar Groet, KD Pharma Group CEO.